Search results
...Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory...
Morningstar· 5 days agoGenentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Combination targeted treatment produces lasting remissions in people with resistant aggressive...
Medical Xpress· 19 hours agoResearchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment...
EHA 2024: Odronextamab shows promise in ELM-2 study for follicular lymphoma
Clinical Trials Arena via Yahoo Finance· 3 days agolymphoma (FL) is a chronic disease that accounts for about 20% of non-Hodgkin's lymphoma (NHL)...
Roche’s Columvi offers extended survival in Phase III DLBCL trial
Clinical Trials Arena via Yahoo Finance· 3 days agoThe trial compared this regimen against MabThera/Rituxan...efficacy of Columvi plus GemOx regimen...
Atezolizumab Consolidation Impresses in High-Risk DLBCL
MedPage Today· 6 days agoPostchemotherapy consolidation with atezolizumab (Tecentriq) led to a surprisingly high 2-year...
Campaign fuels efforts to find better treatments for blood cancers in children
NBC Dallas Fort Worth· 2 days agoLeukemia and Lymphoma Society's (LLS) Dare to Dream project hopes to raise money for research of...
EHA 2024: AstraZeneca’s Calquence plus chemoimmunotherapy offers new standard for MCL
Pharmaceutical Technology via Yahoo Finance· 3 days agoMCL is a rare and often severe form of non-Hodgkin lymphoma (NHL) that develops when B lymphocytes...
EHA 2024: Brukinsa/Venclexta for CLL/SLL lacks control arm in SEQUOIA trial
Clinical Trials Arena via Yahoo Finance· 3 days agoThe median follow-up for the SEQUOIA trial...17p) and/or TP53 mutation were enrolled. The trial...
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
Zacks via Yahoo Finance· 3 days agoRoche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory...
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
The Joplin Globe· 1 day agoTORONTO, ON / ACCESSWIRE / June 19, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research ...